Arcturus Therapeutics Holdings Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$8.25
−$0.08 (−0.90%) 4:00 PM ET
After hours$8.12
−$0.13 (−1.52%) 12:14 AM ET
Prev closePrevC$8.32
OpenOpen$8.20
Day highHigh$8.38
Day lowLow$8.10
VolumeVol288,901
Avg volAvgVol431,439
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$233.85M
P/E ratio
-3.35
FY Revenue
$97.60M
EPS
-2.46
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
ARCT
Arcturus Therapeutics Holdings Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−23% (Below avg)
Vol/Avg: 0.77×
RSI
66.37(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.02 Signal: 0.01
Short-Term
+0.08 (Strong)
MACD: 0.25 Signal: 0.17
Long-Term
+0.07 (Strong)
MACD: 0.34 Signal: 0.27
Intraday trend score
56.00
LOW39.00HIGH57.30
Latest news
ARCT•12 articles•Positive: 6Neutral: 4Negative: 2
NegativeThe Motley Fool• Rick Munarriz
Cathie Wood Goes Shopping: 3 Stocks She Just Bought
Cathie Wood of Ark Invest purchased shares of Robinhood Markets, Netflix, and Arcturus Therapeutics on Wednesday, taking advantage of recent stock price dips and seeing potential growth opportunities in these companies.
Stock halved after disappointing interim trial results, declining revenue for three consecutive years, but potential future growth expected by analysts
NegativeBenzinga• Benzinga Staff Writer
10 Health Care Stocks With Whale Alerts In Today's Session
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034
The Lipid Nanoparticles (LNPs) market is projected to grow from $1 billion in 2024 to $3.5 billion by 2034, driven by increasing demand for mRNA-based therapeutics and advances in drug delivery systems.
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding
The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%, driven by advancements in RNA technologies and next-generation therapies.
ARCTATYRRNA therapeuticsRNA vaccinesnext-generation therapiesbiotechnologymedical research
Sentiment note
Highlighted as a key player in an innovative market with projected high growth and substantial investment interest
NeutralGlobeNewswire Inc.• Researchandmarkets.Com
Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges
The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.
MRNAPFEBNTXCVACfluRNA vaccinesmRNAmarket growth
Sentiment note
Arcturus Therapeutics is mentioned as one of the key players in the flu RNA vaccines market, but the article does not provide any specific details about the company's performance or prospects.
NeutralGlobeNewswire Inc.• Synaptics Incorporated
Synaptics Seeks to Alter the Trajectory of the IoT at Embedded World With Contextual Edge AI and Wireless Innovations
Synaptics is showcasing its latest innovations in Edge AI and wireless connectivity at Embedded World 2025, including a new family of microcontroller units (MCUs) and wireless systems-on-chips (SoCs) designed for ultra-low-power IoT devices with contextually-aware AI and reliable connectivity.
SYNAARCTEdge AIwireless connectivityIoTmicrocontroller unitssystems-on-chipscontextually-aware AI
Sentiment note
Arcturus is mentioned as a specialist in machine vision and a partner for demonstrating AI-enabled industrial vision systems, but no further details are provided about the company.
PositiveBenzinga• Prnewswire
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
The European Commission has approved KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics. KOSTAIVE is the first of its kind to receive approval in Europe and has shown superior immunogenicity and antibody persistence compared to conventional mRNA vaccines.
Arcturus Therapeutics is the co-developer of KOSTAIVE and the article emphasizes the clinical promise of the self-amplifying mRNA technology used in the vaccine. The European Commission's approval of KOSTAIVE is a validation of Arcturus' innovative vaccine platform.
NeutralGlobeNewswire Inc.• Sns Insider
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider
The mRNA therapeutics market is expected to grow significantly, driven by the success of mRNA-based COVID-19 vaccines and the expanding applications of mRNA technology in areas like cancer treatment and infectious diseases.
Arcturus Therapeutics is listed as one of the major players in the mRNA therapeutics market, but the article does not provide any additional information about the company's role or performance.
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way
The mRNA cancer vaccines and therapeutics market is expected to grow rapidly, from $52.85 billion in 2023 to $113.41 billion in 2028, driven by factors like promising clinical trial results, increased awareness, and advancements in mRNA delivery systems. Key trends include personalized medicine and multivalent mRNA vaccines.
PFEMRKBAYRYNVSmRNAcancer vaccinestherapeuticspersonalized medicine
Sentiment note
Arcturus Therapeutics Holdings Inc. is mentioned as one of the leading companies in the mRNA cancer vaccines and therapeutics market, suggesting its active involvement and potential to benefit from the market's growth.
PositiveBenzinga• Vandana Singh
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Arcturus Therapeutics and CSL's self-amplifying mRNA COVID-19 vaccine, ARCT-154, demonstrated superior immunogenicity compared to Pfizer's Comirnaty vaccine, even at a lower dose. The bivalent formula ARCT-2301 also showed better antibody responses against Omicron BA.4-5 and Wuhan-Hu-1 strains.
The article highlights the superior performance of Arcturus Therapeutics' COVID-19 vaccines, ARCT-154 and ARCT-2301, compared to Pfizer's Comirnaty vaccine in terms of immunogenicity and antibody responses.
PositiveBenzinga• Prnewswire
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
Japan's health ministry approved an updated self-amplifying mRNA COVID-19 vaccine developed by CSL and Arcturus Therapeutics, which will be distributed in Japan by Meiji Seika Pharma. The vaccine is designed to protect against the JN.1 Omicron subvariant.
Arcturus Therapeutics is described as a pioneer in self-amplifying mRNA (sa-mRNA) technology, and the article notes that the approved vaccine, KOSTAIVE®, is the world's first commercially available sa-mRNA COVID-19 vaccine. This indicates Arcturus' technological leadership in the mRNA vaccine space.
PositiveBenzinga• Zacks
Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
Wall Street analysts have set a mean price target of $66.75 for Arcturus Therapeutics (ARCT), indicating a potential upside of 216.4%. However, the article cautions that price targets set by analysts may not be a reliable indicator of a stock's future performance.
The article discusses the potential upside for Arcturus Therapeutics based on the consensus price target set by Wall Street analysts, which suggests a 216.4% rally. However, it also notes that price targets should be treated with skepticism, as they may be influenced by business incentives of the firms covering the stock. The article also highlights the positive trend in earnings estimate revisions for Arcturus Therapeutics, which could be a more reliable indicator of the stock's potential upside.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
